Tag Archive for: Fabhalta

Novartis eyes rare kidney disease approvals on heels of two Phase III wins

, ,

Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend.

Read more
/by

Novartis wins first FDA approval for oral monotherapy for rare blood disorder

The Swiss pharma’s Fabhalta, a Factor B inhibitor, is the first FDA-approved oral monotherapy for adults with the rare, chronic blood disorder paroxysmal nocturnal hemoglobinuria.

Read more
/by